GlaxoSmithKline and J&J's HIV Drug Juluca Received Approval In Japan

GlaxoSmithKline plc GSK and partner Johnson & Johnson JNJ announced that Japan's Ministry of Health, Labour and Welfare granted a marketing approval to Juluca for the maintenance treatment of HIV -1 infection.

Juluca combines two approved HIV drugs — Tivicay (50 mg) and Edurant (25 mg) — into a single, once-daily pill for the treatment of virologically suppressed HIV-1 infection.

Tivicay, a novel investigational integrase strand transfer inhibitor (INSTI), is marketed by ViiV Healthcare, an HIV company majorly owned by Glaxo and Pfizer Inc. PFE. Edurant is a non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed by Janssen, J&J's pharma arm. Juluca has been developed under a partnership between ViiV Healthcare and Janssen.

Related Links:

9 Policy Catalysts For Health Care Investors To Watch Before Year's End

The Health Care Stocks With A Lot Riding On The Midterm Elections